Kingsview Wealth Management LLC Buys New Position in Becton, Dickinson and Company $BDX

Kingsview Wealth Management LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 36,685 shares of the medical instruments supplier’s stock, valued at approximately $5,551,000.

Other institutional investors have also added to or reduced their stakes in the company. Auto Owners Insurance Co grew its holdings in Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the period. BlackRock Inc. purchased a new stake in Becton, Dickinson and Company in the second quarter worth about $3,721,533,000. State Street Corp raised its stake in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after buying an additional 116,737 shares during the period. First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock valued at $1,331,165,000 after buying an additional 53,884 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Up 0.8%

NYSE BDX opened at $189.71 on Friday. The stock has a 50 day moving average price of $166.14 and a 200-day moving average price of $160.53. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a market capitalization of $52.27 billion, a P/E ratio of 57.14, a P/E/G ratio of 13.26 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. TD Cowen upped their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. Finally, Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $185.67.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,869 shares of company stock worth $1,994,719 in the last 90 days. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.